Literature DB >> 28358421

Extravasated platelet aggregation in the livers of rats with drug‑induced hepatic sinusoidal obstruction syndrome.

Miki Hirata1, Hidehiro Tajima1, Tomoharu Miyashita1, Takashi Miyata1, Shinichi Nakanuma1, Isamu Makino1, Hironori Hayashi1, Katsunobu Oyama1, Hiroyuki Takamura1, Itasu Ninomiya1, Sachio Fushida1, Hiroki Nakata2, Shoichi Iseki2, Shinichi Harada3, Tomohiko Wakayama4, Tetsuo Ohta1.   

Abstract

Oxaliplatin-based chemotherapy plays an important role in the treatment of colorectal liver metastases. Oxaliplatin, however, causes sinusoidal obstruction syndrome (SOS), which is characterized by portal hypertension, splenomegaly, thrombocytopenia, and liver dysfunction. SOS is diagnosed histopathologically by disruption of the sinusoidal endothelium, collagen deposition, fibrosis especially around zone 3, dilatation of the sinusoidal space and congestion. This study assessed the characteristics of a rat model of SOS. SOS was induced in rats by administration of monocrotaline (MCT). Blood chemistries and macroscopic and microscopic findings were compared in rats administered MCT and vehicle (control group). Levels of expression in the liver of CD41, P‑selectin, rat endothelial cell antigen‑1, CD34, and cleaved caspase‑3 were analyzed immunohistochemically. Moreover, livers of these rats were analyzed by electron microscopy. Macroscopically, MCT‑treated rats showed accumulation of bloody ascites and blue liver and were diagnosed with SOS histologically. Serum concentrations of aspartate aminotransferase (P=0.003), alanine aminotransferase (P=0.008), total‑bilirubin (P=0.012), direct‑bilirubin (P=0.007), indirect‑bilirubin (P=0.003), lactate dehydrogenase (P<0.001) and hyaluronic acid (P=0.016) were significantly higher, and platelet counts significantly lower (P=0.004), in MCT‑treated than in control rats. The livers of MCT‑treated rats were immunohistochemically positive for CD41 and P‑selectin, suggesting platelet aggregates; for rat endothelial cell antigen‑1 and CD34, suggesting sinusoidal endothelial disorder; and for cleaved caspase‑3, suggesting hepatocyte apoptosis. Electron microscopic findings revealed platelet aggregation in the space of Disse in the MCT group. Extravasated platelet aggregation in Disse's space may be involved in the development of SOS.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28358421     DOI: 10.3892/mmr.2017.6407

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

1.  Prophylactic Effect of Recombinant Human Soluble Thrombomodulin for Hepatic Sinusoidal Obstruction Syndrome Model Mice.

Authors:  Shunsuke Kanou; Tomoharu Miyashita; Yasuhiko Yamamoto; Satoshi Takada; Makoto Nakura; Mitsuyoshi Okazaki; Yoshinao Ohbatake; Shinichi Nakanuma; Isamu Makino; Hidehiro Tajima; Hiroyuki Takamura; Sachio Fushida; Tetsuo Ohta
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 2.  A Critical Analysis of Experimental Animal Models of Sinusoidal Obstruction Syndrome.

Authors:  Arvind Kumar; Richard Palek; Vaclav Liska
Journal:  J Clin Exp Hepatol       Date:  2018-07-17

3.  Impact of Bevacizumab on Liver Damage After Massive Hepatectomy in Rats.

Authors:  Hiroki Mori; Y U Saito; Shuichi Iwahashi; Tetsuya Ikemoto; Satoru Imura; Yuji Morine; Mitsuo Shimada
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

4.  Hyaluronic Acid May Be a Predictive Biomarker for Thrombocytopenia and Liver Dysfunction After Oxaliplatin-based Chemotherapy.

Authors:  Takashi Miyata; Yasuto Tomita; Yuta San-Nomiya; Taigo Nagayama; Ryosuke Kin; Hisashi Nishiki; Akifumi Hashimoto; Yoritaka Fujii; Seiko Miura; Daisuke Kaida; Naohiko Nakamura; Tomoharu Miyashita; Hideto Fujita; Nobuhiko Ueda; Hiroyuki Takamura
Journal:  Cancer Diagn Progn       Date:  2022-01-03

5.  Soluble Thrombomodulin Attenuates Endothelial Cell Damage in Hepatic Sinusoidal Obstruction Syndrome.

Authors:  Satoshi Takada; Tomoharu Miyashita; Yasuhiko Yamamoto; Shunsuke Kanou; Seiichi Munesue; Yoshinao Ohbatake; Shinichi Nakanuma; Koichi Okamoto; Seisho Sakai; Jun Kinoshita; Isamu Makino; Keishi Nakamura; Hidehiro Tajima; Hiroyuki Takamura; Itasu Ninomiya; Sachio Fushida; Tetsuo Ohta
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

6.  Pretreatment with a Phosphodiesterase-3 Inhibitor, Milrinone, Reduces Hepatic Ischemia-Reperfusion Injury, Minimizing Pericentral Zone-Based Liver and Small Intestinal Injury in Rats.

Authors:  Shinichi Nakanuma; Hidehiro Tajima; Hiroyuki Takamura; Seisho Sakai; Ryosuke Gabata; Mitsuyoshi Okazaki; Hiroyuki Shinbashi; Yoshinao Ohbatake; Isamu Makino; Hironori Hayashi; Tomoharu Miyashita; Sachio Fushida; Tetsuo Ohta
Journal:  Ann Transplant       Date:  2020-07-14       Impact factor: 1.530

7.  The lysosomal transporter MFSD1 is essential for liver homeostasis and critically depends on its accessory subunit GLMP.

Authors:  David Massa López; Melanie Thelen; Felix Stahl; Christian Thiel; Arne Linhorst; Marc Sylvester; Irm Hermanns-Borgmeyer; Renate Lüllmann-Rauch; Winnie Eskild; Paul Saftig; Markus Damme
Journal:  Elife       Date:  2019-10-29       Impact factor: 8.140

8.  Prognostic factors for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: a multicenter study in China.

Authors:  Haitao Shang; Tao Bai; Shenghua Zhu; Xiaoqian Yang; Chang Liu; Dong Xu; Yuzheng Zhuge; Yuhu Song; Xiaohua Hou
Journal:  Ann Transl Med       Date:  2021-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.